



Atty. Dkt. No. 039386-0536  
Appl. Ser. No. 09/877,633

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Lal et al.

Title: DIAGNOSTIC MARKER FOR  
HUMAN CANCERS

Appl. No.: 09/877,633

Filing Date: 06/08/2001

Examiner: Slobodyansky, Elizabeth


Art Unit: 1652

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

EV 505796837 US September 3, 2004  
(Express Mail Label Number) (Date of Deposit)

Deborah A. Kocorowski  
(Printed Name)

  
(Signature)

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits after the filing of a Request for Continued Examination.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 06-1447. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1447.

Respectfully submitted,

Date 9/3/04

FOLEY & LARDNER LLP  
Customer No. 22428

By M. Scott McBride

M. Scott McBride  
Attorney for Applicant  
Registration No. 52,008  
Telephone: (414) 297-5529  
Facsimile: (414) 297-4900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitution for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: September 3, 2004 (Use as many sheets as necessary)		<b>Complete if Known</b>	
Application Number		09/877,633	
Filing Date		06/08/2001	
Inventor(s):		Lal et al.	
Group Art Unit		1652	
Examiner Name		Slobodyansky, Elizabeth	
Attorney Docket Number		039386-0536	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		BLAST results for SEQ ID NO:1, at National Center for Biotechnology Information database searching for short nearly exact amino acid sequences	
		GenBank Accession No. BAB62751, Submitted by Onouchi et al., <u>unpublished</u>	
		Wakata, et al., <i>Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study</i> , INT. J. DERMATOL., 41:729-34 (2002)	
		Langan et al., <i>Dermatomyositis associated with angiotropic lymphoma</i> , CLIN. DERMATOL., 28:597-599 (2003)	
		Gluck et al., <i>Dermatomyositis, carcinoma of colon and meningioma in the same patient</i> , J. DERMATOL., 20:719-22 (1993)	
		Apaydin et al., J. EUR. ACAD. DERMATOL. VENEREOL., 16:172-4 (2002)	
		Hagman et al., <i>Dermatomyositis associated with ovarian transitional carcinoma</i> , J. AM. ACAD. DERMATOL., 45:642-4 (2001)	
		Di Stasi, et al., <i>Dermatomyositis associated with testicular germ cell cancer</i> , J. UROL., 163:240 (2000)	
		Zhang et al., <i>The Dermatomyositis-Specific Autoantigen Mi2 Is a Component of a Complex Containing Histone Deacetylase and Nucleosome Remodeling Activities</i> , Cell, 95:279-89 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: September 3, 2004

(Use as many sheets as necessary)

2

of

2

**Complete if Known**

Application Number	09/877,633
Filing Date	06/08/2001
Inventor(s):	Lal et al.
Group Art Unit	1652
Examiner Name	Slobodyansky, Elizabeth
Attorney Docket Number	039386-0536

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Targoff, <i>Idiopathic inflammatory myopathy: autoantibody update</i> , CURR. RHEUMATOL. REP., 4:434-41 (2002)	
		GenBank Accession No. NP_060268, Ota et al., Nat. Genet. 36 (1), 40-45 (2004)	
		Stoilov et al., <i>YTH: a new domain in nuclear proteins</i> , TRENDS IN BIOCHEM. SCI., Vol. 27, pp. 495-497 (2002)	
		Targoff et al., <i>Humoral immunity in polymyositis/dermatomyositis</i> , J. INVEST. DERMATOL., 100:116S-123S (1993)	

**Examiner  
Signature**
**Date  
Considered**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.